<DOC>
	<DOC>NCT01662492</DOC>
	<brief_summary>To evaluate the efficacy and safety of Botulinum Toxin Type A versus placebo (normal saline) as headache prophylaxis in adolescents (children 12 to 17) with chronic migraine.</brief_summary>
	<brief_title>A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Medical history of chronic migraine for at least 6 months 15 or more headache days during a 4 week period Previous use of any botulinum toxin of any serotype for any reason Diagnosis of Myasthenia gravis, EatonLambert Syndrome, Amyotrophic Lateral Sclerosis Treatment of headache using acupuncture, transcutaneous electrical stimulation (TENS), cranial traction, dental splints, or injection of anesthetics/steroids within 4 weeks prior to the week 4 screening visit Use of any headache prophylaxis medication within 4 weeks prior to the week 4 screening visit</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>